ReviewSouthern medical journal2015
Beyond PSA: managing modern therapeutic options in metastatic castration-resistant prostate cancer.
Review in Southern medical journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Circulating Tumor DNA as Emerging Predictive and Prognostic Biomarker in Prostate Cancer.Cancers · 2026Review
- Comparative Analysis of ISM-1 and B7-H3 Expression in Castration-Resistant Prostate Adenocarcinoma: Associations with Tumor Aggressiveness and Resistance Dynamics.Medicina (Kaunas, Lithuania) · 2026Article
- Exploratory case series of circulating tumor DNA dynamics during tandem therapy in metastatic castration-resistant prostate cancer.EJNMMI research · 2026Article
- From bench to bedside: the evolution and future of prostate-specific antigen testing.Medical oncology (Northwood, London, England) · 2025Review
- Assessing the effectiveness of MRI,Polish journal of radiology · 2024Article
- Evolving Castration Resistance and Prostate Specific Membrane Antigen Expression: Implications for Patient Management.Cancers · 2021Review
- Article
- Circulating cell-free nucleic acids as prognostic and therapy predictive tools for metastatic castrate-resistant prostate cancer.World journal of clinical oncology · 2020Review
Corrections and comments
- Commented on by
Authors and funding
3 authors.
Funding
Abstract
Prostate cancer remains a significant cause of cancer-related deaths in men in the United States. Significant advances in the treatment of metastatic castration-resistant prostate cancer have been made in recent years with the arrival of new therapeutic targets and options. The definition of progression of disease must be thought of in the context of clinical symptoms and radiographic evidence rather than as changes in prostate-specific antigen (PSA). Ultimately, the use of PSA criteria alone should not be used to determine the progression of disease; instead, PSA should be evaluated in combination with other clinical data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.